Interleukin 12 (IL-12) is a proinflammatory cytokine with antitumor activity. All-trans-retinoic acid (ATRA) exerts antitumor effects by regulating a variety of gene expressions, including tumor necrosis factor receptor 1 (TNFR1), increases the number of TNFR1 and potentiates TNF-a-induced apoptosis in cancer cells. In this study, ATRA-incorporated cationic liposome (ATRA-cationic liposome)/ IL-12 plasmid DNA (pDNA) complexes were prepared to improve therapeutic efficacy of cationic liposome/IL-12 pDNA complexes in a mouse model of metastatic lung tumor after intravenous injection. IL-12 production in lungs by ATRA-cationic liposome/IL-12 pDNA complexes was comparable with that by cationic liposome/IL-12 pDNA complexes. The number of metastatic tumor cells (colon26/Luc) was quantitatively evaluated by measuring luciferase activity. ATRA-cationic liposome/IL-12 pDNA complexes reduced the number of colon26/Luc cells and tumor nodules in lungs. ATRA-cationic liposome/IL-12 pDNA complexes significantly prolonged the survival time of mice, whereas cationic liposome/IL-12 pDNA only slightly prolonged it. ATRA-cationic liposome/IL-12 pDNA complexes increased the TNFR1 mRNA upregulation and the number of apoptotic cells in the lung. Moreover, reduced serum alanine transaminase (ALT) and aspartate transaminase (AST) activities were observed in mice treated with ATRA-cationic liposome/IL-12 pDNA complexes. These results suggest that intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes is an effective method for the treatment of lung metastasis in mice.
Introduction
In recent years, interleukine-12 (IL-12) has become one of the most efficient antitumor cytokines. It exerts its activity by multiple mechanisms including stimulation of a helper T-cell type I response and activation of natural killer cells, and, thereby, the production of interferon-g and tumor necrosis factor-a (TNF-a) that have a cytotoxic effect on tumor cells.
1 IL-12 gene delivery to lungs using intravenously injected cationic liposome/IL-12 plasmid DNA (pDNA) complexes inhibits the growth of metastatic lung tumors. 2 Unfortunately, the enhanced efficacy of IL-12 therapy in clinical applications obtained by increasing its dose is limited because of dose-dependent toxicity. 3 Moreover, the intravenous injection of cationic liposome/pDNA complexes causes proinflammatory cytokine-induced hepatic toxicity because of the recognition of Toll-like receptor 9 to CpG motifs in the pDNA sequence that upregulate the activation of transcription factors, such as nuclear factor-kB (NF-kB), thereby contributing to the production of proinflammatory cytokines from liver macrophages. [4] [5] [6] [7] [8] Therefore, an approach to enhance the antitumor efficacy and reduce the toxicity of cationic liposome/IL-12 pDNA complexes for treatment of metastatic lung tumors is required. Combination therapy has been used to increase the antitumor efficacy and reduce the systemic toxicity of IL-12. Co-administration of IL-12 protein or gene with traditional chemotherapeutic drugs, such as paclitaxel and doxorubicin, inhibits tumor growth and extends the survival time of tumor-bearing mice. 9, 10 However, these traditional chemotherapeutic drugs also kill or stop normal cells dividing rapidly, resulting in marked systemic side effects, such as hematopoietic toxicity. 11, 12 In contrast, differentiation agents have less serious side effects because of their effect on the process of carcinogenesis that tend to make cancer cells revert back to more normal differentiation. [13] [14] [15] Retinoids, for example, are being commonly used in differentiation therapy for cancer treatment. Among retinoids, all-trans-retinoic acid (ATRA) has been widely studied in clinical trials and has become the first-line treatment of acute promyelocytic leukemia. [16] [17] [18] [19] [20] [21] ATRA functions through regulation of a variety of gene expressions that affect the growth and differentiation of cancer cells, including TNF receptor 1 (TNFR1), and it increases the expression of TNFR1 at the cell surface and potentiates the TNF-a-induced apoptosis of human lung cancer cells. 22, 23 Therefore, the combination of IL-12 therapy and ATRA would exert an effect as an effective inhibitor of tumor growth. To date, it is known that ATRA also exerts anti-inflammatory effects by suppressing proinflammatory cytokine production from mesangial cells and macrophages. 24, 25 Motomura et al. 26 and Osteo et al. 27 reported that orally administered ATRA can be used for the treatment of cytokine-induced liver injury and glomerulonephritis in rats. As far as the applications for gene delivery are concerned, suppression of hepatic toxicity mediated by intravenous injection of cationic liposome/pDNA complexes is needed. Recently, we have shown that ATRA incorporated in cationic liposome/pDNA complexes effectively inhibit cytokine production; consequently, hepatic toxicity can be suppressed while the pulmonary transfection efficacy of pDNA encoding luciferase gene is maintained after intravenous injection in mice. 28 Taking these findings into consideration, ATRA incorporated in cationic liposome/pDNA complexes containing IL-12 pDNA is expected to increase the growth inhibition of metastatic lung tumors without producing any serious hepatic toxicity after intravenous injection.
In this study, the complexes of ATRA-incorporated cationic liposome and IL-12 pDNA were prepared, and then the antitumor effects (number of tumor nodules, number of tumor cells and survival rate of mice) after intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes were analyzed in a mouse model of metastatic lung tumors. The apoptotic cells and TNFR1 mRNA expression in lung tissues were also analyzed in a mechanism study. Results were compared with those of cationic liposome/IL-12 pDNA complexes (without ATRA).
Materials and methods
Materials DOTAP (1,2-dioleoyl-3-trimethyl-ammoniopropane) was obtained from Avanti Polar Lipids, Inc. (Alabaster, AL). Cholesterol (Chol) was obtained from Nacalai Tesque Inc. (Kyoto, Japan). ATRA was purchased from Wako Pure Chemicals Industry, Ltd (Osaka, Japan). QIAGEN Endofree Plasmid Giga kit was obtained from QIAGEN GmbH (Hilden, Germany). Luciferase assay buffer (Picagene) was obtained from Toyo Ink Mfg. Co. (Tokyo, Japan). An enzyme-linked immunosorbent assay kit was purchased from R&D Systems, Inc. (Minneapolis). A transaminase C II test kit and an apoptosis in situ detection kit Wako were purchased from Wako Pure Chemical Industries, Ltd. All other chemicals were of the highest purity available.
Animals
Male five-week-old CDF1 mice (20-22 g ) were purchased from the Shizuoka Agricultural Cooperative Association for Laboratory Animals (Shizuoka, Japan). All animal experiments were carried out in accordance with the Principles of Laboratory Animal Care as adopted and promulgated by the US National Institutes of Health and the Guidelines for Animal Experiments of Kyoto University.
Construction and preparation of pDNA pVIVO2-mIL-12 was constructed by inserting the NcoI/ NheI mIL-12 complementary DNA fragment from pORF-mIL-12 (Invivogen, Inc., Diego, CA) into the NcoI/NheI site of pVIVO2-mcs (Invivogen, Inc., Diego, CA). pVIVO2-mIL-12 was amplified in the Escherichia coli strain DH5a, isolated and then purified using a QIAGEN Endofree Plasmid Giga Kit. The concentration of pDNA was determined by measuring ultraviolet absorption at 260 nm.
Preparation of cationic liposomes and ATRA-incorporated cationic liposomes Cationic liposomes and ATRA-incorporated cationic liposomes (ATRA-cationic liposomes) were prepared by the method described previously. 28 ATRA was dissolved in chloroform at a concentration of 1 mg ml -1 . DOTAP and cholesterol were dissolved in chloroform in a molar ratio of 1:1 and then mixed with ATRA in a molar ratio of total lipid to ATRA of 10:1 (for the preparation of ATRA-cationic liposome/IL-12 pDNA complexes) or without it (for the preparation of cationic liposome/IL-12 pDNA complexes). The mixture was vacuum-desiccated, and resuspended in sterile 5% dextrose solution. After hydration, the suspension was sonicated on ice for 3 min and the resulting cationic liposomes were extruded five times through a 220-nm polycarbonate filter.
Preparation of ATRA-cationic liposome/IL-12 pDNA complexes ATRA-cationic liposome/IL-12 pDNA complexes and cationic liposome/IL-12 pDNA complexes were prepared by the method described previously. 28 This involved adding an equal volume of pVIVO2-mIL-12 in 5% dextrose to ATRA-cationic liposomes (for ATRA-cationic liposome/IL-12 pDNA complexes) or cationic liposomes (for cationic liposome/IL-12 pDNA complexes) and leaving at room temperature for 30 min. ATRAcationic liposome/IL-12 pDNA complexes were prepared in charge ratios (À: þ ) of 1.0:3.1 and at a pDNA dose of 1.2 mg kg -1 .
Cancer cells
Murine adenocarcinoma colon26 tumor cells (colon26), obtained from the Cancer Institute of Japan (Tokyo, Japan), were grown in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 0.15% NaHCO 3 , 100 units ml -1 penicillin, 100 mg ml -1 streptomycin and 2 mM L-glutamine at 37 1C in humidified air containing 5% carbon dioxide. As previously described, [29] [30] [31] colon26 cells expressing firefly luciferase (colon26/Luc) were established by transfection with pDNA encoding firefly luciferase under the control of cytomegalovirus immediate-early promoter complexed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA). The cells were then treated with a medium containing 1 mg ml -1 G418 (Geneticin; Sigma, St Louis, MO) and single colonies of G418-resistant cells were picked up and examined for their luciferase activity.
Lung metastasis experiment CDF1 mice were intravenously injected with colon26 cells (1 Â 10 5 ) to establish a model of metastatic lung tumors as reported previously. 32 ATRA-cationic liposome/IL-12 pDNA complexes, cationic liposome/IL-12 pDNA complexes or ATRA-cationic liposomes at a pDNA dose of 1.2 mg kg -1 and an ATRA dose of 0.6 mg kg -1 were intravenously injected into mice at days 3 and 10 after tumor cell injection. At indicated times, blood was collected for measurement of transaminase activity in serum. The survival and weight of the mice were recorded up to 35 days after tumor cell injection. In a separate set of experiments, mice were killed on day 14 after tumor cell injection and the number of tumor nodules on the surface of the lung was counted.
The degree of metastatic lung tumor growth was also evaluated separately by measuring luciferase activity associated with the tumor cells in lung tissue as reported previously. 31 The mouse model of lung tumor metastasis was established by injecting of colon26 cells (1 Â 10 5 ), which stably transfected with firefly luciferase gene (colon26/Luc) in mice, and then the mice were treated as described above. Mice were killed on day 14 after tumor cell injection and the number of colon26/Luc cells in the lung was detected by measuring the luciferase activity.
Measurement of luciferase activity
Lung tissues were homogenized with lysis buffer (0.05% Triton X-100, 2 mmol l -1 EDTA and 0.1 mol l -1 Tris (pH 7.8)), subjected to three cycles of freezing (liquid N 2 for 3 min) and thawing (37 1C, 3 min) and then centrifuged at 10 000 g for 10 min. Then, 20 ml of supernatant was mixed with 100 ml luciferase assay buffer, and the light produced was immediately measured using a luminometer. The measured luciferase activity was converted to the number of colon26/Luc cells in the lung as reported previously. [29] [30] [31] In vitro and in vivo quantification of TNFR1 mRNA Colon26 cells were plated on a 12-well plate at a density of 1 Â 10 5 cells per well. After 24 h, RPMI medium containing 2, 10, 20 and 30 mM ATRA (0.1% dimethylsulfoxide), or dimethylsulfoxide as a control was added to the plates. After a 6-and 12-h incubation, cells were collected for RNA isolation. For in vivo experiments, CDF1 mice were intravenously injected with colon26 cells (1 Â 10 5 ) and with ATRA-cationic liposome/IL-12 pDNA complexes, cationic liposome/IL-12 pDNA complexes, ATRA-cationic liposomes or cationic liposomes at a pDNA dose of 1.2 mg kg -1 and an ATRA dose of 0.6 mg kg -1 at day 3 after tumor cell injection similar to the lung metastasis experiment. Then, 3 and 6 h after injection, the lungs were collected for RNA isolation. The total RNA was isolated from colon26 cells or lung tissues using a GenElute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich Co., St Louis, MO). The quantification of mRNA was measured as described in a previous report. 33 In brief, total RNA was subjected to reverse transcription, which was performed using a PrimeScript RT reagent kit (Takara Bio Inc., Shiga, Japan) according to the manufacturer's instructions. Real-time PCR was performed with a LightCycler 350S system (Roche Diagnostics GmbH, Mannheim, Germany) in LightCycler capillaries. After the addition of SYBR Premix Ex Taq, the primers (final concentration ¼ 0.2 mM) and the template DNA to LightCycler capillaries were subjected to 40 cycles of denaturing (94 1C for 14 s), annealing (58 1C for 30 s) and extension (72 1C for 30 s). After completion of the PCR amplification, a melting curve analysis was performed. Primers were designed by Sigma-Aldrich Japan, Inc. (Tokyo, Japan). The forward and reverse primers for mouse TNFR1 gene (Genebank accession no. M60468) were 5 0 -CAGTCTGCAGGGAGTGTGAA-3 0 and 5 0 -CACGCACTGGAAGTGTGTCT-3 0 . The primers produced a PCR fragment of 197 bp. To ensure that equal amounts of reverse-transcripted complementary DNA were added to the PCR mixture, glyceraldehyde phosphate dehydrogenase was also amplified as the internal control using the following primers: forward primer 5 0 -TC TCCTGCGACTTCAACA-3 0 and reverse primer 5 0 -GCT GTAGCCGTATTCATTGT-3 0 . The primers produced a PCR fragment of 119 bp.
Detection of apoptotic cells in lung CDF1 mice were intravenously injected with colon26 cells (1 Â 10 5 ). After 3 days of tumor cell injection, mice were intravenously injected with ATRA-cationic liposome/IL-12 pDNA complexes, cationic liposome/IL-12 pDNA complexes or ATRA-cationic liposomes; the lungs were removed 24 h later and immediately fixed in 10% neutral buffered formalin overnight. Tissue samples were processed to obtain paraffin-embedded sections and then these tissue sections were prepared for apoptosis detection. Apoptotic cells were determined using an apoptosis in situ detection kit Wako (Wako Pure Chemical Industries, Ltd). The specimens were de-paraffinized and treated according to the provided prescription. The peroxidase activity was visualized with diaminobenzidine substrate, yielding a brown reaction product. The specimens were counterstained with Methyl Green, dehydrated, mounted and inspected under the microscope. A positive control was carried out by pre-incubating a specimen with DNase I and a negative control was carried out by omitting the terminal deoxynucleotidyl transferase enzyme.
ATRA-cationic liposome/IL-12 pDNA complexes in mice P Charoensit et al Measurement of cytokine production in lung Mice were intravenously injected with ATRA-cationic liposome/IL-12 pDNA complexes or cationic liposome/ IL-12 pDNA complexes. At given times, the lung, spleen and liver were collected, homogenized in 1 ml phosphatebuffered saline (À) containing a cocktail of protease inhibitors (aprotinin 2.0 mg ml -1 , leupeptin 1.0 mg ml -1 and Pepstatin A 1.0 mg ml -1 ) and phenylmethanesulfonyl fluoride 100 mg ml -1 . These samples were centrifuged at 10 000 g for 10 min at 4 1C, and then supernatants were collected. The concentrations of IL-12 and TNF-a were immediately determined using an enzyme-linked immunosorbent assay kit for IL-12 and TNF-a, respectively. The concentration of protein in the tissues was measured using a protein quantification kit (Dojindo Laboratories, Inc., Kumamoto, Japan).
Measurement of transaminase activity in serum
The transaminase activity in serum was measured as reported previously. 28 Blood was collected from mice at given times after intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes or cationic liposome/ IL-12 pDNA complexes. After the blood had clotted, samples were centrifuged at 10 000 g for 10 min and the supernatants were collected to obtain serum. Serum alanine transaminase (ALT) and aspartate transaminase (AST) activities were measured with a transaminase C II test kit.
Histological examination of liver
Mice were killed at 24 h after intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes, cationic liposome/IL-12 pDNA complexes or ATRA-cationic liposomes. Lipopoplysaccharide/D-galactosamine-induced liver injury in mice was used as a positive control. 34 Liver was excised and immediately fixed in 10% neutral buffered formalin overnight. Tissue samples were processed to obtain paraffin-embedded sections, and then tissue sections were prepared and stained with hematoxylin and eosin. The histology of the liver sections was examined under a microscope.
Statistical analysis
Statistical analysis was performed using the TukeyKramer test for multiple comparisons among different groups. Statistical analysis of survival curves was carried out using the log-rank test. Po0.05 was considered to be indicative of statistical significance.
Results
The production of IL-12 induced by ATRA-cationic liposome/IL-12 pDNA complexes Figure 1 shows that the intravenously injected ATRAcationic liposome/IL-12 pDNA complexes significantly induced the production of IL-12 in the lungs at 6 and 24 h after injection compared with the non-treatment group. Some degree of induction in the spleen was obtained at 3 h after injection, whereas there was only slight induction in the liver at 3 h after injection. Intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes produced an equal amount of IL-12 in the lungs when compared with that of cationic liposome/IL-12 pDNA complexes.
The effect of ATRA-cationic liposome/IL-12 pDNA complexes on the growth of lung metastatic tumors The intravenously injected ATRA-cationic liposome/ IL-12 pDNA complexes and cationic liposome/IL-12 pDNA complexes reduced by 80 and 60%, respectively, the number of tumor nodules in the lungs of mice, although there was no significant difference in the number of tumor nodules in both groups. The number of tumor nodules in the lungs of mice intravenously injected with ATRA-cationic liposomes was comparable with that of non-treated mice (Figures 2a and b) . The effect of ATRA-cationic liposome/IL-12 pDNA complexes on TNFR1 mRNA expression and TNF-a production A significant increase in the level of TNFR1 mRNA expression in colon26 cells was observed after a 6-and 12-h incubation of ATRA at 10, 20 and 30 mM (Figure 4a) . The intravenously injected ATRA-cationic liposome/IL-12 pDNA complexes and cationic liposome/IL-12 pDNA complexes significantly increased the level of TNFR1 mRNA expression in the lungs at 3 and 6 h after injection (Figure 4b ). The upregulated TNFR1 mRNA induced by ATRA-cationic liposome/IL-12 pDNA complexes was significant higher than that by cationic liposome/IL-12 pDNA complexes at 6 h after injection (Po0.05). The intravenously injected ATRA-cationic liposomes significantly increased the level of TNFR1 mRNA expression in the lungs at 6 h after injection. The cationic liposomes (free ATRA) had no effect on the level of TNFR1 mRNA expression (data not shown). The production of TNF-a in ATRA-cationic liposome/IL-12 pDNA complexes in mice P Charoensit et al the lungs by intravenously injected ATRA-cationic liposome/IL-12 pDNA complexes and cationic liposome/IL-12 pDNA complexes was comparable and significantly higher at 3 and 6 h after injection compared with non-treatment (Figure 4c ).
The effect of ATRA-cationic liposome/IL-12 pDNA complexes on the induction of apoptosis Figure 5 shows that the intravenously injected ATRAcationic liposome/IL-12 pDNA complexes and cationic liposome/IL-12 pDNA complexes induced apoptosis in the lungs at 24 h after injection, and the number of apoptotic cells in the lungs from mice treated with ATRAcationic liposome/IL-12 pDNA complexes was more than that from mice treated with cationic liposome/IL-12 pDNA complexes, whereas no apoptotic cells were observed in ATRA-cationic liposome-treated mice.
The effect of ATRA-cationic liposome/IL-12 pDNA complexes on hepatic toxicity Figures 6a and b show that the intravenously injected ATRA-cationic liposome/IL-12 pDNA complexes and cationic liposome/IL-12 pDNA complexes increased ALT and AST activity in serum. Significantly lower serum ALT and AST activity was produced by ATRA-cationic liposome/IL-12 pDNA complexes at 24 h after injection compared with that produced by cationic liposome/IL-12 pDNA complexes. Liver histology showed that there was severe damage to the liver from mice treated with lipopoplysaccharide and D-galactosamine used as a positive control. There was no inflamed area of liver from mice intravenously injected with ATRA-cationic liposome/IL-12 pDNA complexes and ATRA-cationic liposomes, and some degree of lymphocyte infiltration of the liver was observed in mice intravenously injected with cationic liposome/IL-12 pDNA complexes (Figure 6c ).
Discussion
The ability of intravenously injected ATRA-cationic liposome/IL-12 pDNA complexes to inhibit the growth of metastatic lung tumors was initially analyzed. The preferential IL-12 production in the lungs may be explained by the high lung accumulation of cationic liposome/pDNA complexes at initial time after intravenous injection. 35, 36 IL-12 production in the lungs produced by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes was comparable with that obtained with cationic liposome/IL-12 pDNA complexes (Figure 1 ). Differences in antitumor effects between By counting the number of tumor nodules at the lungs surface, intravenously injected ATRA-cationic liposome/ IL-12 pDNA complexes produced a greater reduction in the number of tumor nodules (Figures 2a and b) . The quantitative method for measuring the number of tumor cells in lung tissues by using colon26/Luc cells showed that the intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes produced a fourfold reduction in the number of colon26/Luc cells in the lungs compared with that of cationic liposome/IL-12 pDNA complexes (Figure 2c ). These greater inhibition effects on tumor growth by ATRA-cationic liposome/IL-12 pDNA complexes supported the significantly prolonged survival time of mice treated with ATRA-cationic liposome/IL-12 pDNA complexes (Po0.001 and Po0.01; Figure 3 ). These findings about cationic liposome/IL-12 pDNA complexes are partly supported by the important work of Dow et al., 2 who reported a decrease in the number of tumor nodules after intravenous injection. Taking these findings into consideration, intravenously injected ATRA-cationic liposome/IL-12 pDNA complexes are able to increase inhibition of the growth of metastatic lung tumors.
We further examined the antitumor mechanism of ATRA-cationic liposome/IL-12 pDNA complexes. TNFR1 expression is upregulated by ATRA and ATRA-cationic liposome/IL-12 pDNA complexes in mice P Charoensit et al cytokines such as interferon-g and IL-1b. 22, 37, 38 Therefore, ATRA-cationic liposome/IL-12 pDNA complexes may produce synergistic effects on TNFR1 upregulation. To date, the upregulation of TNFR1 by ATRA has been reported in human lung cancer cells; 22 however, there have been no reports in mouse colon26 cells. As shown in Figure 4a , ATRA significantly upregulated TNFR1 mRNA expression in mouse colon26 cells in our in vitro study. These in vitro observations by ATRA agree with the in vivo results showing that intravenously injected ATRA-cationic liposome/IL-12 pDNA complexes significantly upregulated TNFR1 mRNA expression in lung metastasis of colon26 cells (Figure 4b ). On the other hand, the production of TNF-a (5-15 pg mg -1 protein) in the lungs by ATRA-cationic liposome/IL-12 pDNA complexes and cationic liposome/IL-12 pDNA complexes ATRA-cationic liposome/IL-12 pDNA complexes in mice P Charoensit et al was comparable (Figure 4c ). As far as the effects of ATRA-cationic liposome/IL-12 pDNA complexes on apoptosis induction in the lungs are concerned, the intravenously injected ATRA-cationic liposome/IL-12 pDNA complexes induced a greater amount of apoptotic cells in lung ( Figure 5 ) that lend support to a greater degree of tumor growth inhibition by ATRA-cationic liposome/IL-12 pDNA complexes (Figures 2 and 3 ). These apoptosis characteristics in the lungs correspond with a previous report that apoptosis in the eyes was induced by TNF-a (approximately 0.2 pg mg -1 protein) and the upregulation of TNFR1 mRNA in mice. 39 Therefore, ATRA incorporated in cationic liposome/IL-12 pDNA complexes might enhance growth inhibition of metastatic lung tumors through an apoptosis pathway induced by the upregulation of TNFR1 in tumors.
An AST level in serum of approximately 70 IU l -1 and a small inflammatory area in the liver histology investigation (g, h) . NT, non-treated mice.
ATRA-cationic liposome/IL-12 pDNA complexes in mice P Charoensit et al were observed in mice treated with cationic liposome/IL-12 pDNA complexes (Figures 6b and c) . These characteristics agree with the report by Car et al. 40 that intraperitoneally injected recombinant IL-12 increased the serum level of AST to 70 IU l -1 and induced macrophage infiltration around the central vein of the liver. To date, the suppressive effects of ATRA on cytokine production have been reported in a number of animal diseases. 24, 26, 27 Recently, Motomura et al. 41 and Kim et al. 25 have shown the suppressive effects of ATRA on cytokine production induced by macrophages. More recently, we have confirmed that ATRA can suppress hepatic nuclear factor-kB activation, proinflammatory cytokine production and hepatic toxicity induced after the intravenous injection of ATRA-cationic liposome/Luc pDNA complexes. 28 In this study we showed that intravenously injected ATRA-cationic liposome/IL-12 pDNA complexes significantly reduced serum ALT and AST activity found together with normal liver histology ( Figure 6 ). These findings suggest that ATRA-cationic liposome/pDNA complexes reduce hepatic toxicity through the anti-inflammatory effects of ATRA.
ATRA exerts an effect through transcriptional regulation of gene expression through retinoic acid receptors and retinoid X receptors in the nucleus of cells. 21 Accordingly, ATRA may affect the transcription of IL-12 pDNA. However, IL-12 production in the lungs, spleen and liver by intravenous injection of ATRAcationic liposome/IL-12 pDNA complexes was comparable with that produced by cationic liposome/IL-12 pDNA complexes (Figure 1 ). These results suggest that ATRA does not affect the production of IL-12 by ATRAcationic liposome/IL-12 pDNA complexes under the experimental conditions used.
In conclusion, it is suggested that intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes can increase inhibition of the growth of metastatic lung tumors through an apoptosis pathway, and that upregulation ATRA-cationic liposome/IL-12 pDNA complexes in mice P Charoensit et al of TNFR1 may be involved in the antitumor mechanism. Reduced ALT and AST activity in serum was observed by ATRA-cationic liposome/IL-12 pDNA complexes under our experimental conditions. These results provide basic information about the application of ATRAcationic liposome/IL-12 pDNA complexes for cancer gene therapy.
